Palvella Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview

Palvella Therapeutics

28/03/2025 12:40

Palvella Therapeutics Inc PVLA.OQ PVLA.O is expected to show a fall in quarterly revenue when it reports  results on March 31 for the period ending December 31 2024

​LSEG's mean analyst estimate for Palvella Therapeutics Inc is for a loss of 67 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".​

Wall Street's median 12-month price target for Palvella Therapeutics Inc is $44.00​, above​ its last closing price of $27.76. ​​​

This summary was machine generated March 28 at 12:40 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)